Pramatarova A, Laganière J, Roussel J, Brisebois K, Rouleau G A
Centre for Research in Neuroscience, McGill University, and the Montreal General Hospital Research Institute, Montreal, Quebec, H3G 1A4, Canada.
J Neurosci. 2001 May 15;21(10):3369-74. doi: 10.1523/JNEUROSCI.21-10-03369.2001.
Mutations were identified in the Cu/Zn superoxide dismutase gene (SOD1) in approximately 15% of patients with familial amyotrophic lateral sclerosis. Transgenic animals expressing mutant SOD1 in all tissues develop an ALS-like phenotype. To determine whether neuron-specific expression of mutant SOD1 is sufficient to produce such a phenotype, we generated transgenic animals carrying the G37R mutation that is associated with the familial form of ALS (FALS), which is driven by the neurofilament light chain promoter. The transgenic animals express high levels of the human SOD1 protein in neuronal tissues, especially in the large motor neurons of the spinal cord, but they show no apparent motor deficit at up to 1.5 years of age. Our animal model suggests that neuron-specific expression of ALS-associated mutant human SOD1 may not be sufficient for the development of the disease in mice.
在大约15%的家族性肌萎缩侧索硬化症患者中,铜锌超氧化物歧化酶基因(SOD1)被发现存在突变。在所有组织中表达突变型SOD1的转基因动物会出现类似肌萎缩侧索硬化症的表型。为了确定突变型SOD1在神经元中的特异性表达是否足以产生这种表型,我们构建了携带与家族性肌萎缩侧索硬化症(FALS)相关的G37R突变的转基因动物,该突变由神经丝轻链启动子驱动。这些转基因动物在神经元组织中,尤其是脊髓的大型运动神经元中,高水平表达人类SOD1蛋白,但在1.5岁之前未表现出明显的运动缺陷。我们的动物模型表明,与肌萎缩侧索硬化症相关的突变型人类SOD1在神经元中的特异性表达可能不足以使小鼠患上该疾病。